

Interim report

January 1 – March 31, 2022

The first quarter in figures

- Net sales were TSEK 5,149 (4,260), +21%.
- The loss after tax was TSEK 10,906 (9,736).
- The loss per share was SEK 0.15 (0.14).
- The cash flow from current operations was negative in the amount of TSEK 3,751 (10,512).
- The gross margin was 68.7% (62.8%).
- Electrode sales volume increased by 16% and were 11,614 (9,982) units. Repeat sales of electrodes to existing customers increased by 11%.

Important events during the quarter

- Overall sales increased by 21% (+13%, before currency effects). Sales in the US skin cancer market were 54% lower than Q1 2022 as Q1-22 included initial Nevisense system sales to US partners. **Sales in Germany increased by 35%** (26% in local currency). Sales within the skin barrier segment increased by 196%.
- After the end of the year the board of directors of SciBase Holding AB (publ), by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders of approximately SEK 79.6 million before transaction costs. The board of directors assesses that, based on the current strategic plan, the capital injection is sufficient for at least the next 12-month period. The subscription price is SEK 1.55 per new share.

The share capital increased by SEK 2,567,816.5 through the issue of 51,356,330 new shares. **SciBase received the issue proceeds after the end of the quarter and after issue costs SciBase received approximately SEK 70 million.**

- **SciBase has entered into a collaboration agreement with Schweiger Dermatology group (SDG)** to pilot Nevisense in two New Jersey practices. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.

Important events after the end of the period

- Two Medicare Administrative Contractors (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas) released updated fee schedules for SciBase's early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. **The updated fee schedules, which now have been increased to levels seen as more appropriate by clinicians, are valid retroactively from January 1st.**
- The summons for the AGM 2023 was published.
- The annual report for 2022 was published.

Financial overview

THE GROUP	Jan 1 – Mar 31		Apr 1, 2022 –	
	2023	2022	Mar 31, 2023 Rolling-12	Jan 1 – Dec 31 2022
Net sales, SEK ths	5 149	4 260	18 778	17 890
Gross margin, %	68,7%	62,8%	64,4%	62,8%
Equity/Asset ratio, %	77,9%	79,3%	78,4%	50,6%
Net indebtedness, multiple	0,28	0,26	0,27	0,98
Cash equivalents, SEK ths	14 394	54 621	14 394	18 832
Cashflow from operating activities, SEK ths	-3 751	-10 512	-37 705	-44 466
Earnings per share (before and after dilution), SEK	-0,15	-0,14	-0,64	-0,63
Shareholder's equity per share, SEK	1,19	0,88	1,05	0,37
Average number of shares, 000 ¹	72 426	68 475	69 463	68 475
Number of shares at closing of period, 000 ^{1*}	119 831	68 475	119 831	68 475
Share price at end of period, SEK	1,80	4,70	1,80	3,82
Number of sold electrodes, pieces	11 614	9 982	43 344	41 712
Average number of employees	21	18	20	20

*Including BTA from ongoing new share issue

Definitions and a glossary are provided on page 18



Nevisense Go

Nevisense Go is a handheld and fully portable device the size of a large Pen. It combines the company's core Electrical Impedance Spectroscopy (EIS) measurement technology with a new AI-based analysis platform embedded in the device. The result is a flexible platform that will be significantly easier to both collect data on and develop applications for. It will also mean products that are easier for clinicians to use and to integrate into a clinic, and better acceptance by patients.

The first Nevisense Go version is released for research in skin barrier assessment and is targeted at researchers and Industry partners.



Comment by CEO Simon Grant

“ Sales momentum in Germany and key US reimbursement decision ”

Q1 Highlights

- Sales in Q1 increased by 21% to MSEK 5.2 (4.3).
- First Coast Service Options (First Coast) and Novitas Solutions (Novitas) updated their fee schedules.
- Fully underwritten rights offering performed.
- SciBase entered into a collaboration agreement with Schweiger Dermatology group.
- Continued sales growth in Germany, +35% in the quarter.

Strong organic usage and sales growth

The first quarter was our 11th quarter of y-o-y quarterly growth and reached a new record high of MSEK 5.2 and a growth of 21% (+13% before currency effects). I was very pleased that we reached this level of growth because it is compared to an exceptional Q1 in 2022 when customers stocked up before our electrode price rise in Europe. The growth continues to be driven by both good electrode and device sales in Germany, where the team delivered 35% growth (26% in local currency). Electrode sales were driven by a strong organic increase in test usage and a 56% increase in the number of new devices sold.

US sales are very dependent upon reimbursement, and this is our key focus in the US. A Medicare fee schedule review planned for the beginning of the year was delayed until April and this contributed to a 54% reduction in US sales in Q1. Two Medicare regions, First Coast (FCSO) and Novitas have now updated their fee schedules and we see good potential to grow sales in these regions going forward.

Interest in the barrier application continues to grow and we have made progress when it comes to sales to industry and researchers. The collaboration with Johnson & Johnson Consumer has spurred interest from both these groups and we expect to see sales, studies and partnerships continue to develop. Barrier sales accounted for 6 (2)% of sales and increased by 196% compared to Q1-22.

With the positive reimbursement decision in the US, a continued high level of interest in the barrier applications and our strong German growth we expect to maintain our positive sales momentum in 2023.


US – Significant progress with Medicare

Our US strategy is based on a stepwise, regional approach, working in partnership with dermatology practice networks (our customers). We have initially focused on Medicare and during last year started to include commercial insurers. **We were very pleased with the news in April that both First Coast (Florida) and Novitas (mid-Atlantic and the central US), who together cover about one third of all seniors in the US, updated their fee schedules for the Nevisense test.** The new rates are applicable retroactively from 1 January 2023. The updated fee schedules have been increased to levels seen as more appropriate by clinicians. We believe that this decision will support the expanded use of the Nevisense test and help us in our efforts to secure broader Medicare and private insurance coverage.

Although Medicare only covers part of the patient population, for us this represents a key patient demographic and it is an important step forward to be able to penetrate the US market. Together with our partners, we will work to expand the availability of the Nevisense test in general, and especially into new regions across the US.

Our strategy is based around partnering with large dermatology practice groups and recently we announced our next collaboration agreement, this time with the Schweiger Dermatology Group. Schweiger is a group including nearly 100 practices, so there is significant potential, and this agreement represents an important step forward for Nevisense in the US.

In March 2023 one of the key US congresses, AAD (American Academy of Dermatology) was held in New Orleans. SciBase remains the only product approved for point-of-care melanoma detection in the US and we believe that the regulatory and clinical evidence requirements continue to provide an important barrier to any competitors wishing to enter this market.



Percentage quarterly sales growth compared to the same quarter in the previous year.

Progress with the barrier applications

The skin barrier area is a strategic focus for SciBase, especially within atopic dermatitis (AD) or eczema. As with NMSC (Non-Melanoma Skin Cancer), the skin barrier products are based on our core EIS technology and electrode but utilize barrier-specific AI algorithms. Because it is a relatively new method and application, we have targeted the research market and industry collaborations first. The collaboration with Johnson & Johnson was our first such industry partnership and with many studies underway or due to start with this exciting technology we see a continuous and growing interest. In Q1 we sold a system and electrodes to MIT in the US and we now have a growing number of leading researchers working with our barrier application. We are focusing on three specific clinical



4

applications where we see a clear path to market and where we see the most interest from both researchers and industry:

1. Infant AD prediction– strategic collaboration with J&J Consumer Health.
2. Objective AD Assessment and management - imminent study start, US.
3. In-home AD flare prediction and management – study ongoing in Germany.

That AD is a burden to society was demonstrated in a recently published article [“Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis”, *Acta Derm Venereol* 2023; 103: adv00881] which investigated the economic and humanistic burden related to atopic dermatitis severity category in pediatric patients with atopic dermatitis and their families. Total costs, both direct and indirect, increased with the severity of atopic dermatitis. The average annual costs for all patients were above € 3,000. The cost for patients with severe AD were over € 5,000 per year. The results emphasize the need for effective new treatment options for children with atopic dermatitis and we believe that SciBase has a key role to play in helping avoid initial onset and managing patients through their treatment.

All of this and a vibrant therapy landscape for atopic diseases illustrate why the skin barrier is a ‘hot’ research area today and we see continually increasing interest in our technology. Nevisense and EIS provide a unique and accessible assessment of the skin barrier that has the potential to become the standard of diagnostic care within this space.

Germany profitable and continues to deliver strong sales growth

Despite a challenging comparable to Q1-22, which saw high stocking sales before a price increase on the electrode, Germany continues to deliver good growth (35%). This is driven by both increased usage as demonstrated by growing electrode sales showing a 16% growth in electrode volumes as well as a 56% increase in device sales. Last April we increased the price of the electrode by 8% which led to all-time high electrode sales in March and April of last year. While many of those sales were customers building stock, what we see now is organic growth in test usage – and


in total we exceeded 10,000 tests in Q1. The increased usage is partly driven by the new Non-Melanoma Skin Cancer (NMSC) indication. More than 50% of all German clinics with Nevisense now have access to the NMSC module. The fact that we now have multiple applications on the same device increases the number of patients that dermatologist can perform a Nevisense measurement on and makes the purchase decision a lot simpler for our customers. At the end of March one of the key congresses in Germany, the Frankenthal congress was held, and interest in our products was at an all-time high.

Company financing

During the first quarter we secured our financing through a fully underwritten rights offering which after issue costs raised around MSEK 70. We were pleased with the subscription outcome, given the challenging current market environment. It is especially pleasing to see that our major shareholders have increased their ownership level. As a company we are at an interesting phase in our development, with many positive things happening and a busy year ahead of us. This funding will enable us to accelerate our activities, especially when it comes to our US sales and marketing and our barrier development.

Opportunities ahead in 2023

2023 has seen a continuation in the high level of interest in Germany and our ability to continue to grow looks promising. We expect further key decisions from US payers during the year as we will accelerate our expansion regionally. Finally, we expect to have multiple clinical and product developments coming within the Barrier area during 2023 – we will continue to be very busy going forward.



Simon Grant, CEO
Sundbyberg May 10th, 2023



SciBase in brief

About SciBase

SciBase, a medical technology company, is a leading developer of augmented intelligence-based solutions for skin disorders. SciBase develops instruments for the detection of skin cancer and other skin conditions such as atopic dermatitis. Nevisense can detect melanoma, the most dangerous form of skin cancer, directly on the skin without needing to cut away suspected moles. The product is based on comprehensive research within Electrical Impedance Spectroscopy (EIS), and SciBase has conducted the largest study to date on the detection of melanoma, in which Nevisense achieved excellent results. The study was published in the prestigious British Journal of Dermatology. Nevisense is approved for sale in the United States (PMA), Europe (CE mark, under MDR) and Australia (TGA).

Besides melanoma, SciBase is developing further research and clinical applications for Nevisense. Using Nevisense as a platform, the Company has added applications based on the same EIS method to assess non-melanoma skin cancer, skin barrier and atopic dermatitis. SciBase sold the first Nevisense systems for the evaluation of the skin barrier function to leading researchers in 2019.

SciBase has also miniaturized the Nevisense hardware platform through the development of an Application Specific Integrated Circuit (ASIC). The new product platform, Nevisense Go, was released at the end of 2020 for research use.

SciBase was founded in 1998 by Associate Professor Stig Ollmar, a researcher at The Karolinska Institute. The Company is headquartered in Sundbyberg, Stockholm and is listed on the Nasdaq First North Growth Market.

Business model

The company's business model is based on customers initially purchasing a Nevisense or Nevisense Go device then buying consumables (electrodes) on an on-going basis. Each electrode can only be used on one patient but can test up to 20 moles or skin areas.

Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- In the United States, expenditure for the treatment of melanoma reached USD 3.3 billion in 2011, equivalent to 41% of expenditure for skin cancer. In the preceding 5-year period, melanoma management cost increased four-fold.
- Today, some 50-60 million annual examinations for melanoma are performed, of which 5-6 million lead to excisions. Of these, some 86-97% are shown to be benign.
- With SciBase's Nevisense® the number of unnecessary interventions can be reduced by up to 50%, representing a reduction of over two million interventions annually and thus leading to significant cost savings.
- The number of patients affected by non-melanoma skin cancer (NMSC) is over ten times the number affected by melanoma. In the US there are approximately 2.8M cases of basal cell carcinoma (a common type of NMSC) each year
- Nevisense® provides physicians with an objective instrument to support better diagnoses.
- Management of atopic dermatitis (eczema) represents the greatest burden globally of all skin diseases. As many as 20 percent of all children and between 1 and 10 percent of all adults are afflicted by atopic dermatitis.





Certified Advisor (CA)

Vator Securities
Email: ca@vatorsec.se
Tel: +46 8 580 065 099

"I work every day with the management of different allergic diseases in children, and it is a growing problem. Allergic diseases have a natural progression with atopic dermatitis being the first to manifest, often already in infancy, followed by other allergic diseases, such as food allergy and allergic asthma. The ability to identify these children early, will help to develop preventive strategies for allergic diseases, and Nevisense is an extremely promising method that has potential for early prediction of those children", says Dr. Caroline Reduit at the Children's Hospital of Eastern Switzerland.

Skin barrier – a hot topic

- Skin barrier related diseases such as food allergy and atopic dermatitis (eczema), are a growing problem and there is a large global unmet need for tools for prediction, measurement and management. The market for atopic dermatitis is expected to grow at ~10% annually until 2030.
- Atopic dermatitis (eczema) is the most common chronic disease worldwide and affects about 20% of infants and 7% of adults.
- Impaired skin barrier is growing with long-term trends such as climate change, increased air pollution, change and loss of biodiversity



First quarter

Net Sales

Net sales for the first quarter of 2023 were TSEK 5,149 (4,260), an increase of 21%. Cleared for currency effects the sales increased by 13%. The increased sales are mainly due to continued good sales of electrodes and devices in Germany, sales of both devices and electrodes for research purposes within the skin barrier application and currency effects. US sales decreased by 54% compared to Q1-22 as the first quarter in 2022 included the initial start-up sales of 5 Nevisense systems to SciBase partners in the US. Germany continues to show a good growth in the quarter (+35%) through both sales of electrodes and sales of devices to new customers. One of the drivers for this growth is the new NMSC (non-melanoma skin cancer) indication.

Sales of devices were TSEK 649 (696) and sales of electrodes to TSEK 4,500 (3,565). The sales within the new skin barrier application were TSEK 300 (101) in the period. These sales are for research purposes. Given the nature of research projects, sales will vary between the quarters.

Sales in Germany in the skin cancer area accounted for 86 (77%) of the sales in the period and increased by 35% compared to Q1 2022. In local currency the sales in Germany increased by 26%. An 8% electrode price increase in Germany from the 1st of April 2022 led to record sales of electrodes in the first quarter of 2022 and thus a relatively tough comparison period.

The sales in the US in the skin cancer segment accounted for 8 (17)% of the sales in the period. Sales in the US are dependent on reimbursement and a first positive reimbursement decision was obtained in April 2023 when two Medicare regions updated the level of reimbursement through their fee-schedule. This enables

expansion and sales within the regions where reimbursement is now in place.

The total sales of electrodes in the quarter reached 11,614 (9,982), an increase of 16%. In Germany, the total sales of electrodes within skin cancer in volume increased by 16% while it decreased by 32% in the US. Total repeat sales of electrodes increased by 11%.

Operating profit/loss

The operating loss for the period January - March 2023 was TSEK 10,783 (9,697), a slightly increased loss of TSEK 1,086. The increased sales and improved margin contributed to an improvement in earnings, which was balanced by increased sales and marketing expenses through increased investments in the US and currency effects. The total operating expenses increased in the period by TSEK 1,949. The operating income was negatively affected by currency effects with around MSEK 0.1.

The gross margin in the period was 68.7 (62.8%). The improved margin is mainly driven by an improved production cost per electrode and currency effects. SciBase is focusing on the margin and the production cost for the electrode and in the quarter the margin for the electrode was close to 75%. When cleared for currency effects the overall gross margin would have been closer to 66%. The overall margin remains very dependent on electrode production and sales volumes and will vary between quarters.

Sales and marketing expenses increased by TSEK 1,642 and was TSEK 8,681 (7,040). The expense increase was primarily due to increased US resources and marketing activities and currency effects.

Administration expenses for the period was TSEK 2,711 (2,582), an increase of TSEK 129. The increase was mainly due to the implementation of a new business system.

Development expenses for the period was TSEK 2,880 (3,090), a decrease of TSEK 210. The decrease is mainly due to decreased product development expenses.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents was TSEK 18,832 and, at the end of the period, was TSEK 14,394.

Cash flow from current operations for the period was negative to the amount of TSEK 3,751 (10,512), of which changes in working capital amounted to positive

TSEK 6,211 (negative 850) which was mainly attributable to decreased receivables. The negative operating cash flow improved mainly following prepaid expenses of clinical trials. Total cash flow for the period was negative to the amount of TSEK 4,682 (11,120). After the end of the period the Company closed a fully underwritten share issue raising net, after issue costs, approximately MSEK 70.

Net investments in tangible assets for the period was TSEK 131 (0). Investments in intangible assets for the period was TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 803 (1,005) of which TSEK 659 (724) are due to leased assets.

Other disclosures

Shareholders

At the end of the period, SciBase Holding AB had approximately 3,437 shareholders. Per April 26, after the performed new share issue the five largest shareholders represented approximately 46.8% of the capital and votes. The total number of shares per April 26, 2023 was 119,831,437. The largest shareholders as per April 26, 2026 were Nordnet Pension (12%), Gell Group (11%), SIX SIS AG – Van Herk (9%), Avanza pension (9%) and Stockholms Elbolag (6%).

Market overview

SciBase is active within both skin cancer detection and skin barrier assessment. SciBase's Nevisense platform addresses multiple sizeable clinical application areas.

Skin cancer

Skin cancer is believed to be the most common form of cancer in the world. More than 3.5 million cases of skin cancer are reported every year in the US alone, which is more than all other cancers combined. Currently around 50 million formal skin cancer screenings are estimated to be performed annually in SciBase's target geographies. The cost for these 50 million screenings is estimated to be around USD 2 billion. SciBase estimates that at least 10-15 percent of patients or more than 7 million lesions are suspicious enough to be excised and examined for melanoma. SciBase estimates that in addition to the 7 million lesions currently excised or biopsied in the company's addressable geographies, there are an additional 1–2 million lesions that are not suspicious enough to excise or biopsy but are still of some concern. Together with the 7 million lesions currently excised SciBase estimate the total addressable market potential for SciBase to be around 400 million USD per year or approximately BSEK 3.7. Of the seven million estimated annual excisions performed in SciBase's target markets around 86–97% are later found to be benign. Uncertainty in the detection of melanoma due to inexperience and limitations of visual screening methods leads

physicians to excise many lesions 'just in case', as physicians do not want to risk missing a melanoma. Despite this over-excision as many as 13% of all melanomas are missed. The excision and biopsy of benign (harmless, i.e., not skin cancers) lesions due to uncertainty of visual screening methods is estimated to cost payers around USD 1.5 billion annually. SciBase estimates that Nevisense could reduce the number of benign lesion excisions by 34–50%.

The population of non-melanoma skin cancer patients includes more than ten times the number of patients compared to the melanoma patient population though the need for testing is not so acute. SciBase estimates that the potential for the use of Nevisense amounts to at least 4 million examinations or tests annually. Given this, non-melanoma skin cancer is estimated to have a total market potential of approximately SEK 1.4 billion annually. Although non-melanoma skin cancer is less harmful than melanoma, SciBase sees the addition of the indication as important for users and necessary to increase market penetration, especially in Germany. Dermatologists see many times more patients with suspected non-melanoma skin cancer than with suspected melanoma, which means that the potential for performing tests with Nevisense is significantly increased.

Skin barrier

An exciting new application area is skin barrier assessment. The skin barrier stops irritants, allergens etc. entering, and water from leaving the body. An impaired skin barrier at birth can be a predictor of the development of Atopic Dermatitis (AD) or eczema. The development of AD often precedes the development of other atopic diseases such as food allergies, allergic rhinitis and allergic asthma. The ability to easily detect an impaired skin barrier can help detect, manage and treat atopic diseases before the development of AD. There is a high interest from the research community and this group is the short-term sales target within the barrier area.

In the application area of the skin's barrier assessment, prediction of disease onset and improving the management of atopic dermatitis are considered to be the largest potential markets. The application area includes disease development prediction in infants, diagnostic and therapy selection tests in a clinical setting, and regular tests in the home in order to monitor and manage the disease. Furthermore, there are many areas within research where the ability to evaluate the skin barrier in a clinical environment or at home has significant value and potential. Given this, the total number of measurements for all patients with atopic dermatitis could potentially exceed the tens of million per year. In the market estimates for skin barrier assessments, the Company expects lower electrode prices. Even so, and only based on two sub-groups (patients with chronic severe recurring eczema episodes and prediction of AD in infants) the total addressable market for the application area skin barrier function is estimated at approximately SEK 3 billion annually.

Initially SciBase targets three areas:

1. Infant AD prediction (clinical and in-home)
2. Objective AD Assessment and management
3. In-home AD flare prediction and management

Employees

At the end of the period, the number of employees amounted to 22 [18], of whom 32 [28]% were women. This includes the production employees at our Uppsala electrode production facility and salespeople in Germany and the US.

Financing

The Board of Directors regularly reviews the company's existing and forecast cash flows to ensure that the company has the funds and resources necessary to pursue operations and strategic focus adopted by the Board. The company's long-term cash requirements are determined by how successful the Company will be able to commercialize its products. Commercialization is, in turn, dependent on a variety of factors that will affect the need, including costs related to being included in insurance systems, granted compensation levels therein, marketing costs and obtaining and enforcing regulatory requirements.

As of March 31, 2023, the Group's cash and cash equivalents amounted to SEK 14.4 million. Based on the current strategic plan, the board assessed that the group needed additional capital during the coming 12-month period. Against the background of that financing need, the board evaluated various financing alternatives. Based on the positive sales development in both the US and Germany as well as the recently announced collaboration with Johnson & Johnson, the board states that the group has achieved important operational and strategic milestones during 2022. Against this background, the board assessed that the company had good conditions to finance the capital requirement that the decided plan requires.

During the first quarter 2023 the board of directors of SciBase Holding AB (publ) has, by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed

issue of new shares with preferential rights for existing shareholders of approximately SEK 79.6 million before transaction costs. The board of directors assesses that, based on the current strategic plan, the capital injection is sufficient for at least the next 12-month period. The subscription price was SEK 1.55 per new share. The share capital increased by SEK 2,567,816.5 through the issue of 51,356,330 new shares. SciBase received the issue proceeds after the end of the first quarter and after issue costs SciBase received approximately SEK 70 million.

Transactions with related parties

During the period, the parent Company SciBase Holding AB has invoiced TSEK 1,186 [1,186] to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the year. In addition, the company has a separate consulting agreement in place with the board member Matt Leavitt (appointed in 2021). The agreement was entered into prior to him being appointed as a board member and relates to consultancy support for the regional reimbursement processes and US market introduction as well as Nevisense rollout guidance following positive reimbursement decisions. The agreement has a one-year duration with the option to extend. In the period he was remunerated KUSD 75 [75] for services under this agreement. During the reporting period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward-looking information. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 34–37 of SciBase's 2022 Annual Report.

Parent Company

SciBase Holding AB (publ), corporate identity number 556773-4768, is the Parent Company of the Group. The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per March 31, 2023, there were two employees, the CEO and the Groups finance department. The operations consist of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the period reached TSEK 1,186 [1,186]. The loss for the period amounted to TSEK 7,430 [7,047]. The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.

The shareholders' contributions to the fully owned subsidiary SciBase AB from 2016 and is charged to earnings and not booked as a financial tangible asset. The shareholders contribution expensed during the period was MSEK 5.9 [5.6].

Significant events during the quarter

After the end of the year the board of directors of SciBase Holding AB (publ), by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders of approximately SEK 79.6 million before transaction costs. The board of directors assesses that, based on the current strategic plan, the capital injection is sufficient for at least the next 12-month period. The subscription price was SEK 1.55 per new share. The share capital increased by SEK 2,567,816.5 through the issue of 51,356,330 new shares. SciBase received the issue proceeds after the end of the quarter and after issue costs SciBase received approximately SEK 70 million. In total, 26,182,918 shares were subscribed for with support of subscription rights, corresponding to approximately 51 percent of the Rights Issue. 12,705,290 shares, corresponding to approximately 25 percent of the Rights Issue, were allotted to persons who have subscribed for shares without support of subscription rights. Therefore, the issue guarantors were allotted approximately 24 percent of the Rights Issue. .

SciBase has entered into a collaboration agreement with Schweiger Dermatology group ("SDG") to pilot Nevisense in their Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut. The agreement will provide Schweiger Dermatology Group's Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.

Significant events after the period

The two Medicare Administrative Contractors (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas) that in the beginning of 2023 performed a review of the fee-schedule for SciBase Nevisense-test have now published an updated fee schedules for SciBase's early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The updated fee schedules are valid retroactively from 1st January 2023 and are available on the MAC's respective webpages.

The summons for the AGM 2023 was published.

The annual report for 2022 was published





Consolidated summary Income Statement

SEK 000'	Jan 1 – March 31		Apr 1, 2022 –	Jan 1 – Dec 31
	2023	2022	Mar 31, 2023 Rolling-12	2022
Net sales	5 149	4 260	18 778	17 890
Cost of goods sold	-1 611	-1 586	-6 680	-6 655
Gross Profit/Loss	3 538	2 674	12 098	11 235
Sales and marketing expenses	-8 681	-7 040	-37 264	-35 623
Administration expenses	-2 711	-2 582	-11 312	-11 183
Development expenses	-2 880	-3 090	-10 606	-10 816
Other operating income	0	0	0	0
Other operating expenses	-49	339	-421	-32
Operating Income	-10 783	-9 697	-47 504	-46 419
Financial income	0	0	3 440	3 440
Financial expenses	-124	-39	-279	-194
Profit/Loss before taxes	-10 906	-9 736	-44 344	-43 174
Income tax	0	0	0	0
Profit/Loss for the period	-10 906	-9 736	-44 344	-43 174
Net Profit/Loss attributable to:				
Parent company shareholders	-10 906	-9 736	-44 344	-43 174
Earnings per share based on Net Profit/loss attributable to parent company shareholders (in SEK/share)				
Profit/loss per share (before and after dilution)*	-0,15	-0,14	-0,64	-0,63
Average number of shares outstanding	72 426	68 475	69 463	68 475

*Profit/loss per share after dilution is not reported, since this would imply improved earnings per share

Consolidated summary statement of comprehensive income

SEK 000'	Jan 1 – March 31		Apr 1, 2022 –	Jan 1 – Dec 31
	2023	2022	Mar 31, 2023 Rolling-12	2022
Profit/loss for the period	-10 906	-9 736	-44 344	-43 174
<i>Other comprehensive income for the period:</i>				
<i>Items that have or may be reclassified to profit or loss:</i>				
assets that can be sold				
Translation differences on foreign operations	249	-823	-1 313	-2 385
Sum other comprehensive income	249	-823	-1 313	-2 385
Total comprehensive income for the period	-10 657	-10 559	-45 657	-45 559
Total comprehensive income attributable to:				
Parent company shareholders	-10 657	-10 559	-45 657	-45 559



Consolidated summary statement of financial position

SEK 000'	Dec 31		Dec 31
	2023	2022	2022
ASSETS			
<i>Fixed Assets</i>			
Tangible fixed assets	1 938	2 125	1 955
Right of use assets	6 506	4 096	7 282
Financial fixed assets	0	0	0
Total Tangible Assets	8 444	6 221	9 237
<i>Current Assets</i>			
Inventory	7 444	6 674	7 292
Current tax receivable	761	706	596
Receivables	4 722	4 569	9 740
Other current receivables	74 477	3 218	4 157
Cash equivalents	14 394	54 621	18 832
Total Current Assets	101 797	69 787	40 617
Total Assets	110 241	76 008	49 854
Shareholders' Equity and Liabilities			
Shareholders' equity attributable to parent company shareholders	85 856	60 237	25 237
<i>Longterm Liabilities</i>			
Other longterm liabilities	4 569	1 883	5 212
Total Longterm Liabilities	4 569	1 883	5 212
<i>Current Liabilities</i>			
Accounts payable	3 121	2 571	1 422
Other current liabilities	16 696	11 317	17 984
Total Current Liabilities	19 816	13 888	19 406
Total Liabilities	24 385	15 771	24 617
Total shareholders' equity and liabilities	110 241	76 008	49 854

Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholders
Opening balance Jan 1, 2022	3 424	637 727	-570 354	70 797
Profit/loss for the period			-9 736	-9 736
Other comprehensive income		-244	-579	-1 402
Total comprehensive income	0	-244	-10 315	-11 138
Total transactions with shareholders	0	0	0	0
Closing balance Mar 31, 2022	3 424	637 483	-580 669	59 659
Opening balance Jan 1, 2023	3 424	637 727	-615 913	25 237
Profit/loss for the period			-10 906	-10 906
Other comprehensive income		0	249	249
Total comprehensive income	0	0	-10 657	-10 657
<i>Transactions with shareholders:</i>				
Ongoing share issue	0	79 602		79 602
Issue expenses		-8 326		-8 326
Total transactions with shareholders	0	71 276	0	71 276
Closing balance Mar 31, 2023	3 424	709 003	-626 571	85 856

Consolidated summary statement of cash flows

SEK 000'	Apr 1, 2022 -			
	Jan 1 - March 31 2023	2022	Mar 31, 2023 Rolling-12	Jan 1 - Dec 31 2022
Cashflow from operating activities before change in working capital	-9 962	-9 662	-42 815	-42 515
<i>Cashflows from changes in working capital</i>				
Change in Inventory	-152	126	-770	-492
Change in Receivables	5 953	-560	-48	-6 560
Change in Liabilities	410	-417	5 929	5 101
<i>Total change in working capital</i>	6 211	-850	5 111	-1 951
Cashflow from operating activities	-3 751	-10 512	-37 705	-44 466
<i>Investment activities</i>				
Acquisitions of Fixed Assets	-131	0	-513	-381
Cashflow from investment activities	-131	0	-513	-381
<i>Financing activities</i>				
New share issues	0	0	0	0
Expenses related to new share issues	-157	0	-157	0
Repayment of lease liabilities	-643	-608	-2 514	-2 479
Cashflow from financing activities	-800	-608	-2 671	-2 479
Cashflow for the period	-4 682	-11 120	-40 889	-47 327
Cash equivalents at start of the year	18 832	65 607	54 621	65 607
Exchange rate differences in cash equivalents	244	134	662	552
Cash equivalents at end of the period	14 394	54 621	14 394	18 832



Income statement, Parent Company

SEK 000'	Jan 1 - Mar 31		Apr 1, 2022 -	
	2023	2022	Mar 31, 2023 Rolling-12	Jan 1 - Dec 31 2022
Net Sales	1 186	1 186	4 744	4 744
Gross profit	1 186	1 186	4 744	4 744
Administration expenses	-2 682	-2 589	-11 303	-11 210
Other expenses	0	-	0	-10
Operating Profit/loss	-1 496	-1 403	-6 559	-6 477
<i>Earnings from financial items:</i>				
Profit/Loss from shares in group companies	-5 934	-5 644	-24 242	-23 952
Financial income	0	0	85	85
Financial expenses	0	0	0	0
Profit/loss after financial items	-7 430	-7 047	-30 801	-30 344
Taxes	-	-	-	-
Profit/loss for the period	-7 430	-7 047	-30 801	-30 344

Statement of other comprehensive income, Parent Company

SEK 000'	Jan 1 - Mar 31		Apr 1, 2022 -	
	2023	2022	Mar 31, 2023 Rolling-12	Jan 1 - Dec 31 2022
Profit/loss for the period	-7 430	-7 047	-30 801	-30 344
<i>Other comprehensive income</i>	-	-	-	-
Total other comprehensive income	-	-	-	-
Total comprehensive income	-7 430	-7 047	-30 801	-30 344



Summary Balance Sheet, Parent Company

SEK 000'	Dec 31		Dec 31
	2023	2022	2022
ASSETS			
<i>Fixed Assets</i>			
Shares in Group Companies	137 647	137 647	137 647
Total Fixed Assets	137 647	137 647	137 647
<i>Current Assets</i>			
Current receivables and prepaids	103 853	47 883	30 397
Cash equivalents	1 285	16 018	10 794
Total Current Assets	105 139	63 902	41 190
TOTAL ASSETS	242 785	201 548	178 837
SHAREHOLDERS' EQUITY AND LIABILITIES			
<i>Shareholder's equity</i>			
Restricted equity			
Share capital	3 424	3 424	3 424
Non-restricted equity			
Other capital contributions	708 886	637 610	637 610
Retained earnings	-465 544	-435 380	-435 380
Profit/Loss for the period	-7 430	-7 047	-30 344
Shareholders equity	239 335	198 606	175 309
<i>Current Liabilities</i>			
Current liabilities	3 450	2 942	3 527
Total liabilities	3 450	2 942	3 527
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	242 785	201 549	178 837



Notes

Note 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report with the exception of what is stated below. Significant accounting and valuation principles are detailed on pages 47–52 of the consolidated annual report for 2022.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Note 3 Contingent Liabilities

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB to secure that the equity at minimum corresponds to the share capital that is valid until the end of 2023. A corresponding agreement was in-place in 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today two operating segments, skin cancer and skin barrier assessment. Follow-ups are in addition done on the geographical areas, Europe, US/North America and Asia/Oceania.

First quarter

Skin cancer

Europe

Net sales during the period amounted to TSEK 4,446 (3,286) of which Germany accounted for 100 (100)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. Gross profit amounted to a profit of TSEK 3,012 (1,965).

Other geographical areas

Net sales during the period amounted to TSEK 403 (874). Gross profit amounted to TSEK 337 (638). The sales consisted mainly of electrode sales to larger dermatology groups. Q1–22 included the sales of 5 Nevisense to the Company's partners in the US.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe

Net sales during the period amounted to TSEK 173 (0). Gross profit amounted to a profit of TSEK 97 (0). The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 127 (101). Gross profit amounted to TSEK 91 (72). The sales were to researchers and industry within the skin barrier field.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Note 6 Incentive program

The Group has no outstanding warrants. The Board considers it as important and positive if the employees' ownership in the company increases. The Board has evaluated different incentive programs and following this decided to implement a normal bonus program. The goals are set by the board and normally consist of turnover goals and other strategic goals. After the end of the year, it is then assessed how well the goals have been met. However, the purpose of the program is to increase the employees' ownership in the company. The board sees increased ownership by the employees as positive as it increases the employees' incentive for the company to succeed through, for example, increased sales and thereby creating increased shareholder value. Thus, if the employee undertakes to buy shares over the market and enter into a lockup agreement (12-months), the bonus is increased by 4 times the cash bonus. The program has a maximum ceiling (including social security fees etc of SEK 3 million), the total cost for 2022 was SEK 0.9 (1.7) million.

Operating segments

SEK 000'	Jan 1 - Mar 31, 2023			Jan 1 - Mar 31, 2022		
	Europe	Rest of the World	Total	Europe	Rest of the World	Total
Skincancer - Net sales	4 446	403	4 849	3 286	874	4 160
The skin barrier function - Net Sales	173	127	300	0	101	101
Sales between segments	-	-	-	-	-	-
Net sales from external customers	4 619	530	5 149	3 286	975	4 260
Cost of goods - Skincancer	-1 434	-66	-1 500	-1 321	-237	-1 557
Cost of goods - Barrier function	-75	-36	-111	0	-29	-29
Cost of goods - total	-1 510	-101	-1 611	-1 321	-266	-1 586
Gross Profit - Skincancer	3 012	337	3 349	1 965	638	2 602
Gross Profit - Barrier function	97	91	188	0	72	72
Gross Profit - total	3 109	429	3 538	1 965	709	2 674
Operating expenses			-14 321			-12 372
Operating profit/Loss			-10 783			-9 697
Financial Income			0			0
Financial Expenses			-124			-39
Group earnings - before tax			-10 906			-9 736

Net sales per category and segment

Amounts in KSEK	Jan 1 - Mar 31 2023		Jan 1 - Mar 31 2022		Rolling-12		Full Year 2022	
	Europe	Rest of the World	Europe	Rest of the World	Europe	Rest of the World	Europe	Rest of the World
<i>Skin cancer</i>								
Electrodes	3 964	403	3 038	524	13 328	1 918	12 402	2 038
Instruments	483	0	247	350	1 532	219	1 297	570
Total Skin Cancer	4 446	403	3 286	874	14 860	2 137	13 699	2608
<i>Skin barrier function</i>								
Electrodes	104	29	0	3	379	630	275	604
Instruments	68	98	0	98	182	590	114	590
Total skin barrier function	173	127	0	101	562	1 220	389	1194
<i>Total</i>								
Electrodes	4 068	432	3 038	526	13 707	2 547	12 677	2 642
Instruments	551	98	247	449	1 714	809	1 411	1 160
Total	4 619	530	3 286	975	15 422	3 357	14 088	3802

Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

[SciBase Holding AB]
Stockholm, May 10, 2023

Tord Lendau
Chairman of the Board

Diana Ferro
Board member

Thomas Taapken
Board member

Matt Leavitt
Board member

Jvalini Dwarkasing
Board member

Simon Grant
CEO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 10, 2023.

This year-end report has not been subject to review by the Company's auditors

This report, together with previously published interim reports, can be found in its entirety on the company's website: <http://investors.scibase.se/en/reports-and-presentations>

Contact person:
Michael Colérus, CFO, +46 70 341 34 72

Quarterly overview

THE GROUP	2023		2022		2021				
	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Net sales, SEK ths	5 149	4 962	4 941	3 726	4 260	3 925	2 982	2 258	2 562
Gross margin, %	68,7%	61,4%	58,4%	70,6%	62,8%	52,8%	63,3%	56,3%	52,7%
Equity/Asset ratio, %	77,9%	50,6%	72,5%	76,6%	79,3%	82,8%	86,8%	87,3%	79,6%
Net indebtedness, multiple	0,28	0,98	0,38	0,30	0,26	0,21	0,15	0,15	0,26
Cash equivalents, SEK ths	14 394	18 832	34 014	44 577	54 621	65 607	78 270	88 192	31 403
Cashflow from operating activities, SEK ths	-3 751	-14 593	-9 718	-9 643	-10 512	-11 709	-9 156	-9 162	-9 473
Earnings per share (before and after dilution), SEK	-0,15	-0,23	-0,13	-0,13	-0,14	-0,20	-0,13	-0,19	-0,15
Shareholder's equity per share, SEK	1,19	0,37	0,57	0,72	0,88	1,03	1,24	1,59	0,70
Average number of shares, 000'	72 426	68 475	68 475	68 475	68 475	68 475	68 475	59 265	54 780
Number of shares at closing of period, 000'	119 831	68 475	68 475	68 475	68 475	68 475	68 475	68 236	54 780
Share price at end of period, SEK	1,80	3,82	3,70	3,41	4,70	5,52	4,88	5,52	4,78
Number of sold electrodes, pieces	11 614	11 444	10 592	9 550	9 982	8 024	8 304	5 968	7 496
Average number of employees	21	21	20	19	18	18	17	17	18

Definitions

Financial key ratios

- **TSEK:** SEK 000'
- **Gross margin, %:** Gross profit divided by net sales.
- **Operating profit:** Operating income less operating expenses.
- **Operating margin, %:** Operating profit divided by income.
- **Equity/assets ratio:** Equity at the end of the period divided by total assets at the end of the period.
- **Debt/equity ratio:** Total liabilities in relation to equity.
- **Earnings per share for the period before dilution:** Profit for the period divided by average number of shares before dilution.
- **Earnings per share for the period after dilution:** Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- **Shareholders' equity per share:** Equity divided by average number of shares.
- **Dividend per Share:** Dividend for the period divided by average number of shares after dilution.
- **Number of shares before dilution at the end of the period:** Number of shares in issue before dilution at the end of the period.
- **Average number of shares before dilution:** Average number of shares during the period before dilution.
- **Average number of shares after dilution:** Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- **Number of employees (average):** Weighted average number of employees in the relevant period.
- **IFRS:** International Financial Reporting Standards

Industry specific glossary

- **CE labeling:** A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA, or intended for sale there.
- **Dermatoscopy or Dermoscopy:** Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- **Electrical Impedance Spectroscopy (EIS):** A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- **FDA:** The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- **Melanoma:** The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- **Unnecessary excision:** The removal of benign skin lesions/birthmarks.
- **Nevi:** Lesions.
- **PMA:** Pre-Market Approval, a form of approval from the US FDA required for all new Class III devices.

Alternative performance measures (APM)

This section contains a reconciliation of certain alternate performance measures (APM) against the most reconcilable items in the financial statements. The reporting of APMs has limitations as analytical tools and should not be viewed without context or as compensation for financial measures prepared in accordance with IFRS. APMs are reported to improve investors' evaluation of ongoing operating profit, as a means of predicting future periods, and to simplify a meaningful comparison of results between periods. Management uses these APMs to evaluate, among other things, ongoing operations compared with previous results, for internal planning and forecasting, as well as for calculation of certain performance-related compensation. The APMs reported in this interim report may differ from measures with similar terms used by other companies.

APM for the period:

Gross Margin (%)

	2022	2021
Gross Profit	3 538	2 674
Net Sales	5 149	4 260
Gross Margin (%)	68,7%	62,8%

Definition:

Gross Profit / Loss divided with Net Sales.

Cause of use:

The gross margin shows the difference between net sales and the cost of goods sold in % of net sales. The gross margin is affected by several factors such as product mix, price trends, exchange rate fluctuation, efficiency in manufacturing processes etc. This is an important measurement as it provides a better understanding of the Company's progress.

Shareholder Equity ratio (%)

	2022	2021
Total Shareholders' Equity	85 856	60 237
Total Assets	110 241	76 008
Shareholders' Equity ratio (%)	77,9%	79,3%

Definition:

Total Shareholders' Equity at the end of the period divided with Total Assets at the end of the year.

Cause of use:

Shareholders equity ratio shows the Group's financial sustainability and the portion that is financed by equity.

Debt ratio (times)

	2022	2021
Total Liabilities	24 385	15 771
Total Shareholders' Equity	85 856	60 237
Debt ratio (times)	0,28	0,26

Definition:

Total debt in relation to Total Shareholders' Equity.

Cause of use:

The debt ratio indicates how much debt the Company is using to finance its assets relative to the value of of shareholders' equity. It is closely connected to the Shareholder's equity ratio.

Earnings per share, after dilution (sek)

	2022	2021
Profit/Loss for the period	-10 906	-9 736
Average number of shares (thousand)	72 426	68 475
Earnings per share (sek)	-0,15	-0,14

Definition:

Is the portion of a company's profit allocated to each outstanding share of common stock after dilution. The result per share after the dilution is no different than before the dilution due to that potential common stock do not give rise to a dilution effect.

Cause of use:

This shows the value per share.

Shareholders' equity per share (sek)

	2022	2021
Shareholders' Equity	85 856	60 237
Average number of shares (thousand)	72 426	68 475
Shareholders' equity per share	1,19	0,88

Definition:

Shareholders' equity divided with the average number of shares after dilution

Cause of use:

The shareholders' equity per share provides a measure of the net worth per share and can be set in relation to the actual stock price

Average number of shares (thousand)

	2022	2021
Opening balance - Jan 1	68 475	54 780
Closing balance - Mar 31	119 831	68 475
Average number of shares (thousand)	72 426	68 475

Definition:

The average number of issued shares.

Cause of use:

The average number of shares gives a more accurate picture of the result and shareholders' equity due to the fact that the number of shares can change.



Simon Grant
CEO
+46 72 887 43 99
simon.grant@scibase.com

Read more about the company and its operations at our website >> www.scibase.com



Michael Colérus
CFO
+46 70 341 34 72
michael.colerus@scibase.com

Future reporting dates

AGM 2023, May 17 2023

Interim report Q2, August 18 2023

Interim report Q3, November 10 2023